These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Management of high-risk non-muscle invasive bladder cancer. Brausi M; Olaru V Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212 [TBL] [Abstract][Full Text] [Related]
24. The value of a second transurethral resection for T1 bladder cancer. Schwaibold HE; Sivalingam S; May F; Hartung R BJU Int; 2006 Jun; 97(6):1199-201. PubMed ID: 16566814 [TBL] [Abstract][Full Text] [Related]
25. Feasibility and Clinical Roles of Different Substaging Systems at First and Second Transurethral Resection in Patients with T1 High-Grade Bladder Cancer. Colombo R; Hurle R; Moschini M; Freschi M; Colombo P; Colecchia M; Ferrari L; Lucianò R; Conti G; Magnani T; Capogrosso P; Conti A; Pasini L; Burgio G; Guazzoni G; Patriarca C Eur Urol Focus; 2018 Jan; 4(1):87-93. PubMed ID: 28753746 [TBL] [Abstract][Full Text] [Related]
26. Impact of second opinion pathology in the definitive management of patients with bladder carcinoma. Coblentz TR; Mills SE; Theodorescu D Cancer; 2001 Apr; 91(7):1284-90. PubMed ID: 11283928 [TBL] [Abstract][Full Text] [Related]
27. Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy. Ark JT; Keegan KA; Barocas DA; Morgan TM; Resnick MJ; You C; Cookson MS; Penson DF; Davis R; Clark PE; Smith JA; Chang SS BJU Int; 2014 Jun; 113(6):894-9. PubMed ID: 24053444 [TBL] [Abstract][Full Text] [Related]
28. A new tool for distinguishing muscle invasive and non-muscle invasive bladder cancer: the initial application of flexible ultrasound bronchoscope in bladder tumor staging. Xu C; Zhang Z; Wang H; Song Q; Wei R; Yu Y; Li J; Sun Y PLoS One; 2014; 9(4):e92385. PubMed ID: 24704988 [TBL] [Abstract][Full Text] [Related]
29. The Impact of Tumor Diameter and Tumor Necrosis on Oncologic Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. Soave A; John LM; Dahlem R; Minner S; Engel O; Schmidt S; Kluth LA; Fisch M; Rink M Urology; 2015 Jul; 86(1):92-8. PubMed ID: 26051839 [TBL] [Abstract][Full Text] [Related]
30. Smoothelin immunohistochemistry is a useful adjunct for assessing muscularis propria invasion in bladder carcinoma. Bovio IM; Al-Quran SZ; Rosser CJ; Algood CB; Drew PA; Allan RW Histopathology; 2010 Jun; 56(7):951-6. PubMed ID: 20636795 [TBL] [Abstract][Full Text] [Related]
31. Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder. Abufaraj M; Shariat SF; Foerster B; Pozo C; Moschini M; D'Andrea D; Mathieu R; Susani M; Czech AK; Karakiewicz PI; Seebacher V World J Urol; 2018 Feb; 36(2):231-240. PubMed ID: 29127452 [TBL] [Abstract][Full Text] [Related]
32. Risk factors for disconcordance between pre and post radical cystectomy stages. Saadat SH; Al-Tawil MO Urol J; 2011; 8(4):291-7. PubMed ID: 22090048 [TBL] [Abstract][Full Text] [Related]
33. Invasive bladder cancer in the eighties: transurethral resection or cystectomy? Faba OR; Palou J; Urdaneta G; Gausa L; Villavicencio H Int Braz J Urol; 2011; 37(1):49-55;discussion 55-6. PubMed ID: 21385480 [TBL] [Abstract][Full Text] [Related]
34. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101 [TBL] [Abstract][Full Text] [Related]
35. Does radical cystectomy outperform other bladder preservative treatments in elderly patients with advanced bladder cancer? Chen CL; Liu CY; Cha TL; Hsu CY; Chou YC; Wu ST; Meng E; Sun GH; Yu DS; Tsao CW J Chin Med Assoc; 2015 Aug; 78(8):469-74. PubMed ID: 26074367 [TBL] [Abstract][Full Text] [Related]
36. Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. Turker P; Bostrom PJ; Wroclawski ML; van Rhijn B; Kortekangas H; Kuk C; Mirtti T; Fleshner NE; Jewett MA; Finelli A; Kwast TV; Evans A; Sweet J; Laato M; Zlotta AR BJU Int; 2012 Sep; 110(6):804-11. PubMed ID: 22321341 [TBL] [Abstract][Full Text] [Related]
37. EORTC progression score identifies patients at high risk of cancer-specific mortality after radical cystectomy for secondary muscle-invasive bladder cancer. May M; Burger M; Brookman-May S; Stief CG; Fritsche HM; Roigas J; Zacharias M; Bader M; Mandel P; Gilfrich C; Seitz M; Tilki D Clin Genitourin Cancer; 2014 Aug; 12(4):278-86. PubMed ID: 24331576 [TBL] [Abstract][Full Text] [Related]
38. A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable. van Kessel KE; van de Werken HJ; Lurkin I; Ziel-van der Made AC; Zwarthoff EC; Boormans JL PLoS One; 2017; 12(3):e0174039. PubMed ID: 28319171 [TBL] [Abstract][Full Text] [Related]
39. [Radical cystectomy in the treatment of bladder cancer always in due time?]. May M; Braun KP; Richter W; Helke C; Vogler H; Hoschke B; Siegsmund M Urologe A; 2007 Aug; 46(8):913-9. PubMed ID: 17676301 [TBL] [Abstract][Full Text] [Related]